bioAffinity Technologies, Inc.

BIAF

NASDAQ

Healthcare

Medical - Diagnostics & Research

San Antonio, TX, US57 employeesbioaffinitytech.com

$3.89

-0.09(-2.26%)

Mkt Cap $17M

$0.75

$21.00

52-Week Range

At a Glance

AI-generated

bioAffinity Technologies reported a net loss of $14.9 million for FY 2025, a significant increase from a $9.0 million loss in FY 2024, despite raising $16.9 million in gross proceeds from equity transactions.

Revenue breakdown: Laboratory Services (47.7%), Health Care Patient Service (45%), Histology Service Fees (6.8%).

8-K

bioAffinity Technologies announced Q1 2026 CyPath® Lung unit sales exceeded internal projections with 146% year-over-year growth based on preliminary unaudited data.

$17M

Market Cap

$16M

Revenue

-$39M

Net Income

Employees57

Fundamentals

How The Business Makes Money

Revenue by Segment

Laboratory Services47.7%($16M)

Health Care Patient Service45%($15M)

Histology Service Fees6.8%($2M)

Medical Director Fees0.4%($134.8K)

Other Revenues0%($12.2K)

Department Of Defense Observational Studies0%($9.2K)

Diagnostic Research And Development0%($9.2K)

Activity

What Changed Recently

Management Change

Mar 5, 2026

. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 5,

Financial Results

Mar 12, 2026

and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securi

Other Event

Mar 31, 2026

. Other Events.** On April 1, 2026, bioAffinity Technologies, Inc., a Delaware corporation, issued a press release announcing that unit sales for its CyPath® Lu

Regulation FD

Mar 25, 2026

and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the

Other Event

Mar 9, 2026

. Other Events. On March 10, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing the initiation of i

Peer Companies

Company	Price	Change	Market Cap	P/E
ARTLArtelo Biosciences, Inc.	$7.19	-8.29%	$15M	-1.4
SLRXSLRX	$0.84	+29.23%	$5M	—
GTBPGT Biopharma, Inc.	$0.44	+7.01%	$5M	-0.1
REVBRevelation Biosciences, I...	$1.22	-0.80%	$2M	-0.8
CARMCarisma Therapeutics, Inc...	$0.04	+4.26%	$2M	0.2
PTIXProtagenic Therapeutics, ...	$0.53	+1.92%	$1M	-0.3
LIPOLipella Pharmaceuticals I...	$0.16	-8.00%	$744.0K	-0.1
MNDRMobile-health Network Sol...	$0.84	+1.38%	$742.3K	-0.9

Analyst View

Company Profile

CIK0001712762

ISINUS09076W3079

CUSIP09076W307

Phone210 698 5334

Address22211 West Interstate 10, San Antonio, TX, 78257, US

SEC EDGAR